Kenvue (US:KVUE) Yahoo Finance·2025-10-23 07:13Core Insights - Kenvue Inc. is a consumer health company with a market cap of $28.7 billion, operating in various segments including Self Care, Skin Health and Beauty, and Essential Health, and owns well-known brands like Listerine and Tylenol [1] Financial Performance - Kenvue is expected to report an adjusted EPS of $0.27 for Q3, a decrease of 3.6% from $0.28 in the same quarter last year, but has a strong history of meeting or exceeding earnings estimates [2] - For fiscal 2025, Kenvue's adjusted EPS is projected to be $0.99, down 13.2% from $1.14 in 2024, with a rebound expected in fiscal 2026 to $1.12 per share, reflecting a 13.1% year-over-year increase [3] Stock Performance - Kenvue's stock has declined by 33.8% over the past 52 weeks, significantly underperforming the Consumer Staples Select Sector SPDR Fund's 2.8% dip and the S&P 500 Index's 14.5% gain during the same period [4] - Following the release of mixed Q2 results, Kenvue's stock gained 1.5%, despite a 4.2% drop in organic sales and an overall topline decline of 4% year-over-year to $3.8 billion, which missed expectations [5] Analyst Sentiment - Analysts maintain a consensus "Moderate Buy" rating for Kenvue, with six "Strong Buys," nine "Holds," and one "Strong Sell" among 16 analysts, and a mean price target of $20.36 indicating a 34% upside potential from current levels [6]